Epigenomics ADRs to Trade in US | GenomeWeb

NEW YORK (GenomeWeb News) – Epigenomics today said that it has established a Level 1 American Depositary Receipt program enabling the firm to trade publicly in the US.

The Berlin, Germany-based molecular diagnostics firm said that its ADRs are US dollar-negotiable certificates that represent ordinary shares of the company at a ratio of five ordinary shares to one Epigenomics ADR.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.